Volume | 916,861 |
|
|||||
News | - | ||||||
Day High | 38.40 | Low High |
|||||
Day Low | 37.05 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Vera Therapeutics Inc | VERA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
37.62 | 37.05 | 38.40 | 37.99 | 36.95 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,024 | 916,861 | $ 37.92 | $ 34,768,627 | - | 7.73 - 50.78 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:38:08 | 3 | $ 39.09 | USD |
Vera Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.69B | 44.43M | - | 0 | -95.99M | -2.16 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vera Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VERA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 37.31 | 39.39 | 35.91 | 37.08 | 857,558 | 0.68 | 1.82% |
1 Month | 44.96 | 48.51 | 35.91 | 40.59 | 705,419 | -6.97 | -15.50% |
3 Months | 44.13 | 50.65 | 35.855 | 42.05 | 935,734 | -6.14 | -13.91% |
6 Months | 13.78 | 50.78 | 13.07 | 35.60 | 1,043,974 | 24.21 | 175.69% |
1 Year | 8.00 | 50.78 | 7.73 | 27.31 | 849,212 | 29.99 | 374.88% |
3 Years | 17.25 | 50.78 | 5.20 | 22.19 | 418,000 | 20.74 | 120.23% |
5 Years | 11.41 | 50.78 | 5.20 | 22.17 | 414,022 | 26.58 | 232.95% |
Vera Therapeutics Description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |